Overcoming therapeutic obstacles in inflammatory bowel diseases: A comprehensive review on novel drug delivery strategies

European Journal of Pharmaceutical Sciences

Volumn 49, Issue 4, 2013, Pages 712-722

  Talaei, F ^a   Atyabi, F ^a   Azhdarzadeh, M ^a   Dinarvand, R ^a   Saadatzadeh, A ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Biological therapy; IBD; Microparticles; Nanopartiles; Prodrug systems

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; DEXAMETHASONE; ETHYL CELLULOSE; EUDRAGIT; GELATIN; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE; NANOPARTICLE; NATALIZUMAB; POLYCAPROLACTONE; PROBIOTIC AGENT; PRODRUG; SALICYLIC ACID DERIVATIVE; TACROLIMUS; TYSARBI; UNCLASSIFIED DRUG;

ABDOMINAL CRAMP; BIOLOGICAL THERAPY; CROHN DISEASE; CUSHING SYNDROME; DIARRHEA; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG FEVER; ENTERIC COATED TABLET; ENTERITIS; FLATULENCE; HAIR LOSS; HEADACHE; HEPATITIS; HIRSUTISM; HUMAN; IN VITRO STUDY; KIDNEY DISEASE; MALAISE; MICROCAPSULE; NAUSEA; NAUSEA AND VOMITING; NEPHRITIS; NONHUMAN; OSMOTIC PUMP; OSTEOPOROSIS; PANCREATITIS; PANCYTOPENIA; PRESSURE; PRIORITY JOURNAL; REMISSION; REVIEW; SLEEP DISORDER; STOMATITIS; SUSTAINED DRUG RELEASE; TREMOR; ULCERATIVE COLITIS;

EID: 84879491455     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2013.04.031     Document Type: Review

References (109)

1. Akhgari, A., Garekani, H.A., Sadeghi, F., Azimaie, M., 2005. Statistical optimization of indomethacin pellets coated with pH-dependent methacrylic polymers for possible colonic drug delivery. Int. J. Pharm. 305, 22-30. (Pubitemid 41562214)
2. Ali Asghar, L.F., Chandran, S., 2006. Multiparticulate formulation approach to colon specific drug delivery: current perspectives. J. Pharm. Pharm. Sci. 9, 327-338. (Pubitemid 46614339)
3. Arranz, A., Reinsch, C., Papadakis, K.A., Dieckmann, A., Rauchhaus, U., Androulidaki, A., Zacharioudaki, V., Margioris, A.N., Tsatsanis, C., Panzner, S., 2013. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J. Control. Release 165, 163-172.
4. Ashford, M., Fell, J., Attwood, D., Sharma, H., Woodhead, P., 1993a. An evaluation of pectin as a carrier for drug targeting to the colon. J. Control. Release 26, 213-220. (Pubitemid 23287366)
5. Ashford, M., Fell, J.T., Attwood, D., Woodhead, P.J., 1993b. An in vitro investigation into the suitability of pH-dependent polymers for colonic targeting. Int. J. Pharm. 91, 241-245. (Pubitemid 23159828)
6. Atyabi, F., Majzoob, S., 2008. Polysaccharides as Carrier for Particulate-controlled Delivery Systems. Journal of Biomedical Nanotechnology 2, 750.
7. Atyabi, F., Vahabzadeh, R., Dinarvand, R., 2004. Preparation of ethylcellulose coated gelatin microspheres as a multiparticulate colonic delivery system for 5- aminosalicilic acid. Iran. J. Pharm. Res. 3, 81-86.
8. Baker, D.E., 2004. Adalimumab: human recombinant immunoglobulin G1 antitumor necrosis factor monoclonal antibody. Rev. Gastroenterol. Disord. 4, 196-210. (Pubitemid 40012219)
9. Banić, M., Anić, B., Brkić, T., 1997. Animal models of inflammatory bowel disease. Acta medica Croatica: casopis Hravatske akademije medicinskih znanosti 51, 37-40.
10. Bausserman, M., Michail, S., 2005. The use of lactobacillus GG in irritable bowel syndrome in children: a double-blind randomized control trial. J. Pediatrics 147, 197-201. (Pubitemid 41207833)
11. Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J., van Deventer, S.J.H., Neirynck, S., Peppelenbosch, M.P., Steidler, L., 2006. A phase I trial with transgenic bacteria expressing interleukin-10 in Crohn's disease. Clin. Gastroenterol. Hepatol. 4, 754-759. (Pubitemid 43841860)
12. Camma, C., Giunta, M., Rosselli, M., Cottone, M., 1997. Mesalamine in the maintenance treatment of Crohn's disease: a meta-analysis adjusted for confounding variables. Gastroenterology 113, 1465-1473. (Pubitemid 27461232)
13. Carbonnel, F., Jantchou, P., Monnet, E., Cosnes, J., 2009. Environmental risk factors in Crohn's disease and ulcerative colitis: an update. Gastroentérologie clinique et biologique 33 (Suppl. 3), S145-157.
14. Chourasia, M.K., Jain, S.K., 2003. Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm. Sci. 6, 33-66. (Pubitemid 37207241)
15. Cui, F., Qian, F., Yin, C., 2006. Preparation and characterization of mucoadhesive polymer-coated nanoparticles. Int. J. Pharm. 316, 154-161. (Pubitemid 43765702)
16. Friend, D.R., 2005. New oral delivery systems for treatment of inflammatory bowel disease. Adv. Drug Deliv. Rev. 57, 247-265. (Pubitemid 39536101)
17. Friend, D.R., Chang, G.W., 1985. Drug glycosides: potential prodrugs for colonspecific drug delivery. J. Med. Chem. 28, 51-57. (Pubitemid 15156296)
18. Fukui, E., Miyamura, N., Kobayashi, M., 2001. An in vitro investigation of the suitability of press-coated tablets with hydroxypropylmethylcellulose acetate succinate (HPMCAS) and hydrophobic additives in the outer shell for colon targeting. J. Control. Release 70, 97-107. (Pubitemid 32144796)
19. Fukui, E., Miyamura, N., Uemura, K., Kobayashi, M., 2000. Preparation of enteric coated timed-release press-coated tablets and evaluation of their function by in vitro and in vivo tests for colon targeting. Int. J. Pharm. 204, 7-15.
20. Gliko-Kabir, I., Yagen, B., Penhasi, A., Rubinstein, A., 1998. Low swelling, crosslinked guar and its potential use as colon-specific drug carrier. Pharm. Res. 15, 1019-1025. (Pubitemid 28356917)
21. Guagnozzi, D., Lucendo, A.J., 2012. Colorectal cancer surveillance in patients with inflammatory bowel disease: what is new? World J. Gastrointest. Endosc. 4, 108-116.
22. Gupta, A.S., Kshirsagar, S.J., Bhalekar, M.R., Saldanha, T., 2013. Design and development of liposomes for colon targeted drug delivery. J. Drug Target. 21, 146-160.
23. Hamman, J.H., 2010. Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems. Mar. Drugs 8, 1305-1322.
24. Hanauer, S.B., Sparrow, M., 2004. Therapy of ulcerative colitis. Curr. Opin. Gastroenterol. 20, 345-350. (Pubitemid 38813676)
25. Hardy, J.G., Davis, S.S., Khosla, R., Robertson, C.S., 1988. Gastrointestinal transit of small tablets in patients with ulcerative colitis. Int. J. Pharm. 48, 79-82.
26. Harris, M.L., Schiller, H.J., Reilly, P.M., Donowitz, M., Grisham, M.B., Bulkley, G.B., 1992. Free radicals and other reactive oxygen metabolites in inflammatory bowel disease: cause, consequence or epiphenomenon? Pharmacol. Ther. 53, 375-408.
27. Hegazy, S.K., El-Bedewy, M.M., 2010. Effect of probiotics on pro-inflammatory cytokines and NF-jb activation in ulcerative colitis. World J. Gastroenterol. 16, 4145-4151.
28. Hita, V., Singh, R., Jain, S.K., 1997. Colonic targeting of metronidazole using azo aromatic polymers: development and characterization. Drug Deliv.: J. Deliv. Target. Ther. Agents 4, 19-22. (Pubitemid 27146182)
29. Ibekwe, V.C., Fadda, H.M., Parsons, G.E., Basit, A.W., 2006. A comparative in vitro assessment of the drug release performance of pH-responsive polymers for ileocolonic delivery. Int. J. Pharm. 308, 52-60. (Pubitemid 43097235)
30. Jenita, J.J.L., Vijaya, K., Suma, R., Raj, B., Siddiqca, A., 2010. Formulation and evaluation of compression coated tablets of mesalazine for colon delivery. Int. J. PharmTech. Res. 2, 535-541.
31. Jones, A.S.C., 2006. Inflammatory bowel disease - drug treatment and its implications. Hosp. Pharmacist 13, 161-166.
32. Jonkers, D., Penders, J., Masclee, A., Pierik, M., 2012. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs 72, 803-823.
33. Kawadkar, J., Ram, A., 2007. Colon targeted chitosan microsphere compressed matrices for the treatment of ulcerative colitis. Pharm. Rev. 5.
34. Kesisoglou, F., Zhou, S.Y., Niemiec, S., Lee, J.W., Zimmermann, E.M., Fleisher, D., 2005. Liposomal formulations of inflammatory bowel disease drugs: local versus systemic drug delivery in a rat model. Pharm. Res. 22, 1320-1330. (Pubitemid 41176036)
35. Khan, M.Z.I., Štedul, H.P., Kurjaković, N., 2000. A pH-dependent colon-targeted oral drug delivery system using methacrylic acid copolymers. II. Manipulation of drug release using Eudragit® L100 and Eudragit S100 combinations. Drug Dev. Ind. Pharm. 26, 549-554. (Pubitemid 30225633)
36. Klotz, U., 2000. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. Eur. J. Clin. Pharmacol. 56, 353-362. (Pubitemid 30666060)
37. Kreuter, J., 1991. Peroral administration of nanoparticles. Adv. Drug Deliv. Rev. 7, 71-86.
38. Kriegel, C., Amiji, M., 2011. Oral TNF-a gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease. J. Control. Release 150, 77-86.
39. Krishnaiah, Y.S.R., Satyanarayana, V., Kumar, B.D., Karthikeyan, R.S., Bhaskar, P., 2003. In vivo pharmacokinetics in human volunteers: oral administered guar gum-based colon-targeted 5-fluorouracil tablets. Eur. J. Pharm. Sci. 19, 355-362. (Pubitemid 36952397)
40. Kruis, W., Frič, P., Pokrotnieks, J., Lukáš, M., Fixa, B., Kaščák, M., Kamm, M.A., Weismueller, J., Beglinger, C., Stolte, M., Wolff, C., Schulze, J., 2004. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut 53, 1617-1623. (Pubitemid 39434105)
41. Kruis, W., Schutz, E., Fric, P., Fixa, B., Judmaier, G., Stolte, M., 1997. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 11, 853-858.
42. Kuhbacher, T., Fölsch, U.R., 2007. Practical guidelines for the treatment of inflammatory bowel disease. World J. Gastroenterol. 13, 1149-1155. (Pubitemid 46592953)
43. Lamprecht, A., Schäfer, U., Lehr, C.M., 2001a. Size-dependent bioadhesion of microand nanoparticulate carriers to the inflamed colonic mucosa. Pharm. Res. 18, 788-793. (Pubitemid 32783514)
44. Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Lehr, C.M., Maincent, P., Kawashima, Y., 2001b. Design of rolipram-loaded nanoparticles: comparison of two preparation methods. J. Control. Release 71, 297-306. (Pubitemid 32276049)
45. Lamprecht, A., Ubrich, N., Yamamoto, H., Schäfer, U., Takeuchi, H., Maincent, P., Kawashima, Y., Lehr, C.M., 2001c. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J. Pharmacol. Exp. Ther. 299, 775-781.
46. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., 2003. Microsphere design for the colonic delivery of 5-fluorouracil. J. Control. Release 90, 313-322. (Pubitemid 36859963)
47. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., 2005a. A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J. Control. Release 104, 337-346. (Pubitemid 40724934)
48. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., 2005b. Nanoparticles enhance therapeutic efficiency by selectively increased local drug dose in experimental colitis in rats. J. Pharmacol. Exp. Ther. 315, 196-202. (Pubitemid 41380512)
49. Lamprecht, A., Yamamoto, H., Takeuchi, H., Kawashima, Y., 2004. Design of pHsensitive microspheres for the colonic delivery of the immunosuppressive drug tacrolimus. Eur. J. Pharm. Biopharm. 58, 37-43. (Pubitemid 38781002)
50. Lasic, D.D., 1998. Novel applications of liposomes. Trends Biotechnol. 16, 307-321. (Pubitemid 28305254)
51. Leopold, C.S., Eikeler, D., 2000. Basic coating polymers for the colon-specific drag delivery in inflammatory bowel disease. Drug Dev. Ind. Pharm. 26, 1239-1246. (Pubitemid 32037420)
52. Li, A.C.Y., Thompson, R.P.H., 2003. Basement membrane components. J. Clin. Pathol. 56, 885-887. (Pubitemid 37533227)
53. Lichtenstein, G.R., 2001. Is infliximab effective for induction of remission in patients with ulcerative colitis? Inflamm. Bowel Dis. 7, 89-93. (Pubitemid 32998494)
54. Lin, S.Y., Ayres, J.W., 1992. Calcium alginate beads as core carriers of 5- aminosalicylic acid. Pharm. Res. 9, 1128-1131.
55. Mannon, P.J., Fuss, I.J., Mayer, L., Elson, C.O., Sandborn, W.J., Present, D., Dolin, B., Goodman, N., Groden, C., Hornung, R.L., Quezado, M., Neurath, M.F., Salfeld, J., Veldman, G.M., Schwertschlag, U., Strober, W., 2004. Anti-interleukin-12 antibody for active Crohn's disease. N. Engl. J. Med. 351, 2069-2079. (Pubitemid 39482500)
56. McClean, S., Prosser, E., Meehan, E., O'Malley, D., Clarke, N., Ramtoola, Z., Brayden, D., 1998. Binding and uptake of biodegradable poly-DL-lactide micro- and nanoparticles in intestinal epithelia. Eur. J. Pharm. Sci. 6, 153-163. (Pubitemid 28164286)
57. Meissner, Y., Pellequer, Y., Lamprecht, A., 2006. Nanoparticles in inflammatory bowel disease: particle targeting versus pH-sensitive delivery. Int. J. Pharm. 316, 138-143. (Pubitemid 43765696)
58. Milojevic, S., Newton, J.M., Cummings, J.H., Gibson, G.R., Louise Botham, R., Ring, S.G., Stockham, M., Allwood, M.C., 1996. Amylose as a coating for drug delivery to the colon: preparation and in vitro evaluation using 5-aminosalicylic acid pellets. J. Control. Release 38, 75-84. (Pubitemid 26027181)
59. Nakase, H., Okazaki, K., Tabata, Y., Chiba, T., 2003. Biodegradable microspheres targeting mucosal immune-regulating cells: new approach for treatment of inflammatory bowel disease. J. Gastroenterol. 38, 59-62. (Pubitemid 36442889)
60. Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Matsushima, Y., Kawanami, C., Oshima, C., Ikada, Y., Chiba, T., 2000. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: a new therapeutic strategy. J. Pharmacol. Exp. Ther. 292, 15-21. (Pubitemid 30026351)
61. Nakase, H., Okazaki, K., Tabata, Y., Uose, S., Ohana, M., Uchida, K., Nishi, T., Debreceni, A., Itoh, T., Kawanami, C., Iwano, M., Ikada, Y., Chiba, T., 2001. An oral drug delivery system targeting immune-regulating cells ameliorates mucosal injury in trinitrobenzene sulfonic acid-induced colitis. J. Pharmacol. Exp. Ther. 297, 1122-1128. (Pubitemid 32472512)
62. Neuman, M.G., Nanau, R.M., 2012. Inflammatory bowel disease: role of diet, microbiota, life style. Transl. Res. 160, 29-44.
63. Nikolaus, S., Rutgeerts, P., Fedorak, R., Steinhart, A.H., Wild, G.E., Theuer, D., Möhrle, J., Schreiber, S., 2003. Interferon β-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut 52, 1286-1290. (Pubitemid 37026460)
64. Okazaki, K., Nakase, H., Watanabe, N., Tabata, Y., Ikada, Y., Chiba, T., 2002. Intestinal drug delivery systems with biodegradable microspheres targeting mucosal immune-regulating cells for chronic inflammatory colitis. J. Gastroenterol. 37, 44-52. (Pubitemid 35385926)
65. Papadakis, K.A., Shaye, O.A., Vasiliauskas, E.A., Ippoliti, A., Dubinsky, M.C., Birt, J., Paavola, J., Lee, S.K., Price, J., Targan, S.R., Abreu, M.T., 2005. Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am. J. Gastroenterol. 100, 75-79. (Pubitemid 41623272)
66. Park, J., Floch, M.H., 2007. Prebiotics, probiotics, and dietary fiber in gastrointestinal disease. Gastroenterol. Clin. North Am. 36, 47-63. (Pubitemid 46654719)
67. Pertuit, D., Moulari, B., Betz, T., Nadaradjane, A., Neumann, D., Ismaïli, L., Refouvelet, B., Pellequer, Y., Lamprecht, A., 2007. 5-Amino salicylic acid bound nanoparticles for the therapy of inflammatory bowel disease. J. Control. Release 123, 211-218. (Pubitemid 350007824)
68. Pichai, M.V., Ferguson, L.R., 2012. Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases. World J. Gastroenterol. 18, 2895-2901.
69. Rahimi, R., Nikfar, S., Abdollahi, M., 2007. Meta-analysis technique confirms the effectiveness of anti-TNF-a in the management of active ulcerative colitis when administered in combination with corticosteroids. Med. Sci. Monit. 13, PI13- PI18. (Pubitemid 47037680)
70. Rahimi, R., Nikfar, S., Rahimi, F., Elahi, B., Derakhshani, S., Vafaie, M., Abdollahi, M., 2008. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig. Dis. Sci. 53, 2524-2531.
71. Reiff, C., Kelly, D., 2010. Inflammatory bowel disease, gut bacteria and probiotic therapy. Int. J. Med. Microbiol. 300, 25-33.
72. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., Chalmers, D.M., Axon, A.T.R., 1999. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet 354, 635-639. (Pubitemid 29391428)
73. Rodríguez, M., Vila-Jato, J.L., Torres, D., 1998. Design of a new multiparticulate system for potential site-specific and controlled drug delivery to the colonic region. J. Control. Release 55, 67-77. (Pubitemid 28477565)
74. Rubinstein, A., 1990. Microbially controlled drug delivery to the colon. Biopharm. Drug Dispos. 11, 465-475. (Pubitemid 20271436)
75. Rubinstein, A., 2005. Colonic drug delivery. Drug Discov. Today: Technol. 2, 33-37. (Pubitemid 40946306)
76. Rutgeerts, P., Sandborn, W.J., Feagan, B.G., Reinisch, W., Olson, A., Johanns, J., Travers, S., Rachmilewitz, D., Hanauer, S.B., Lichtenstein, G.R., De Villiers, W.J.S., Present, D., Sands, B.E., Colombel, J.F., 2005. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462-2476. (Pubitemid 41770166)
77. Rutgeerts, P.J., 2004. An historical overview of the treatment of Crohn's disease: why do we need biological therapies? Rev. Gastroenterol. Disord. 4, S3-S9. (Pubitemid 39600212)
78. Saadatzadeh, A., Atyabi, F., Fazeli, M.R., Dinarvand, R., Jamalifar, H., Abdolghaffari, A.H., Mahdaviani, P., Mahbod, M., Baeeri, M., Baghaei, A., Mohammadirad, A., Abdollahi, M., 2011. Biochemical and pathological evidences on the benefit of a new biodegradable nanoparticles of probiotic extract in murine colitis. Fundamental and Clinical Pharmacology.
79. Sandborn, W.J., Colombel, J.F., Enns, R., Feagan, B.G., Hanauer, S.B., Lawrance, I.C., Panaccione, R., Sanders, M., Schreiber, S., Targan, S., Van Deventer, S., Goldblum, R., Despain, D., Hogge, G.S., Rutgeerts, P., 2005. Natalizumab induction and maintenance therapy for Crohn's disease. N. Engl. J. Med. 353, 1912-1925. (Pubitemid 41565956)
80. Sandborn, W.J., Hanauer, S., Loftus Jr., E.V., Tremaine, W.J., Kane, S., Cohen, R., Hanson, K., Johnson, T., Schmitt, D., Jeche, R., 2004. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am. J. Gastroenterol. 99, 1984-1989. (Pubitemid 39421244)
81. Sangalli, M.E., Maroni, A., Zema, L., Busetti, C., Giordano, F., Gazzaniga, A., 2001. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J. Control. Release 73, 103-110. (Pubitemid 32409351)
82. Scheline, R.R., 1973. Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 25, 451-532.
83. Schreiber, S., Rutgeerts, P., Fedorak, R.N., Khaliq-Kareemi, M., Kamm, M.A., Boivin, M., Bernstein, C.N., Staun, M., Thomsen, O.Ø., Innes, A., 2005. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 129, 807-818. (Pubitemid 41242673)
84. Seldenrijk, C.A., Drexhage, H.A., Meuwissen, S.G.M., Pals, S.T., Meijer, C.J.L.M., 1989. Dendritic cells and scavenger macrophages in chronic inflammatory bowel disease. Gut 30, 484-491.
85. Shanahan, F., 2004. Probiotics in inflammatory bowel disease - therapeutic rationale and role. Adv. Drug Deliv. Rev. 56, 809-818. (Pubitemid 38520101)
86. Shen, E.H., Das, K.M., 2004. Current therapeutic recommendations: infliximab for ulcerative colitis. J. Clin. Gastroenterol. 38, 741-745. (Pubitemid 39274172)
87. Siew, L.F., Man, S.M., Newton, J.M., Basit, A.W., 2004. Amylose formulations for drug delivery to the colon: a comparison of two fermentation models to assess colonic targeting performance in vitro. Int. J. Pharm. 273, 129-134. (Pubitemid 38317047)
88. Sinha, V.R., Kumria, R., 2001a. Colonic drug delivery: prodrug approach. Pharm. Res. 18, 557-564. (Pubitemid 32595781)
89. Sinha, V.R., Kumria, R., 2001b. Polysaccharides in colon-specific drug delivery. Int. J. Pharm. 224, 19-38. (Pubitemid 32706482)
90. Sinha, V.R., Kumria, R., 2003a. Coating polymers for colon specific drug delivery: a comparative in vitro evaluation. Acta Pharm. 53, 41-47. (Pubitemid 36514234)
91. Sinha, V.R., Kumria, R., 2003b. Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. 18, 3-18. (Pubitemid 36120550)
92. Sutherland, L., Roth, D., Beck, P., May, G., Makiyama, K., 2002. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst. Rev. (Online: Update Software).
93. Tabata, Y., Inoue, Y., Ikada, Y., 1996. Size effect on systemic and mucosal immune responses induced by oral administration of biodegradable microspheres. Vaccine 14, 1677-1685. (Pubitemid 27041922)
94. Takaya, T., Sawada, K., Suzuki, H., Funaoka, A., Matsuda, K.-I., Takada, K., 1997. Application of a colon delivery capsule to 5-aminosalicylic acid and evaluation of the pharmacokinetic profile after oral administration to beagle dogs. J. Drug Target. 4, 271-276. (Pubitemid 27239014)
95. Talaei, F., 2012. Aberrations in proteostasis orchestrate: the genotypic and phenotypic changes in aging. Am. J. Mol. Cell. Biol. 1, 1-16.
96. Talaei, F., Azizi, E., Dinarvand, R., Atyabi, F., 2011. Thiolated chitosan nanoparticles as a delivery system for antisense therapy: evaluation against EGFR in T47D breast cancer cells. Int. J. Nanomed. 6, 1963-1975.
97. Tirosh, B., Khatib, N., Barenholz, Y., Nissan, A., Rubinstein, A., 2009. Transferrin as a luminal target for negatively charged liposomes in the inflamed colonic mucosa. Mol. Pharm. 6, 1083-1091.
98. Van Assche, G., Van Ranst, M., Sciot, R., Dubois, B., Vermeire, S., Noman, M., Verbeeck, J., Geboes, K., Robberecht, W., Rutgeerts, P., 2005a. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N. Engl. J. Med. 353, 362-368. (Pubitemid 41132340)
99. Van Assche, G., Vermeire, S., Rutgeerts, P., 2005b. Medical treatment of inflammatory bowel diseases. Curr. Opin. Gastroenterol. 21, 443-447. (Pubitemid 40961171)
100. Varshosaz, J., Emami, J., Tavakoli, N., et al., 2011. Development of novel budesonide pellets based on CODESTM technology: in vitro/in vivo evaluation in induced colitis in rats. DARU, Journal of Pharmaceutical Sciences. 19(2), 107-117.
101. Vinderola, G., Matar, C., Palacios, J., Perdigón, G., 2007. Mucosal immunomodulation by the non-bacterial fraction of milk fermented by Lactobacillus helveticus R389. Int. J. Food Microbiol. 115, 180-186. (Pubitemid 46367331)
102. Watts, P.J., Barrow, L., Steed, K.P., Wilson, C.G., Spiller, R.C., Melia, C.D., Davies, M.C., 1992. The transit rate of different-sized model dosage forms through the human colon and the effects of a lactulose-induced catharis. Int. J. Pharm. 87, 215-221.
103. Watts, P.J., Lllum, L., 1997. Colonic drug delivery. Drug Dev. Ind. Pharm. 23, 893-913. (Pubitemid 27406363)
104. Wilson, D.S., Dalmasso, G., Wang, L., Sitaraman, S.V., Merlin, D., Murthy, N., 2010. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9, 923-928.
105. Wong, D., Larrabee, S., Clifford, K., Tremblay, J., Friend, D.R., 1997. USP dissolution apparatus III (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J. Control. Release 47, 173-179. (Pubitemid 27212344)
106. Xiao, B., Merlin, D., 2012. Oral colon-specific therapeutic approaches toward treatment of inflammatory bowel disease. Expert Opin. Drug Deliv. 9, 1393-1407.
107. Yang, R., Shim, W.S., Cui, F.D., Cheng, G., Han, X., Jin, Q.R., Kim, D.D., Chung, S.J., Shim, C.K., 2009. Enhanced electrostatic interaction between chitosan-modified PLGA nanoparticle and tumor. Int. J. Pharm. 371, 142-147.
108. Zema, L., Maroni, A., Foppoli, A., Palugan, L., Sangalli, M.E., Gazzaniga, A., 2007. Different HPMC viscosity grades as coating agents for an oral time and/or sitecontrolled delivery system: an investigation into the mechanisms governing drug release. J. Pharm. Sci. 96, 1527-1536. (Pubitemid 46953768)
109. Zigra, P.I., Maipa, V.E., Alamanos, Y.P., 2007. Probiotics and remission of ulcerative colitis: a systematic review. Neth. J. Med. 65, 411-418.